Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP & Chief Medical Officer | March 20, 2019 | March 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date March 20, 2019 · Filed March 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 · Expires 2028-01-24 | Direct | 75,000 |
Reported balance
After 2019-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-20 · Grant · Acquired 75,000 · Balance 75,000 F1: On January 24, 2018, the reporting person was granted a performance based option to purchase 75,000 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 24, 2018, the reporting person was granted a performance based option to purchase 75,000 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2019 Filed Mar 22, 2019 23:19 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-004206 · edgar.xml · derivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: On January 24, 2018, the reporting person was granted a performance based option to purchase 75,000 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:23 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 162,500 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000933 · edgar.xml · derivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 22:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-18-011567 · edgar.xml · derivative · entry 6 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest over four (4) years from January 1, 2017. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 22:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmploye Stock Option (right to buy) · Derivative | 115,500 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001179110-18-011567 · edgar.xml · derivative · entry 5 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,000 Underlying: Common Stock · 115,500 shares Expires 2026-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One fourth (1/4th) of the option vests one (1) year from March 7, 2016 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 22:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 37,500 | $3.50 | $131,250.00 |
DisclosureSEC source: 0001179110-18-011567 · edgar.xml · nonDerivative · entry 4 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 22:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 37,500 | $2.11 | $79,125.00 |
DisclosureSEC source: 0001179110-18-011567 · edgar.xml · nonDerivative · entry 3 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 22:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 115,500 | $3.50 | $404,250.00 |
DisclosureSEC source: 0001179110-18-011567 · edgar.xml · nonDerivative · entry 2 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 22:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 115,500 | $2.54 | $293,370.00 |
DisclosureSEC source: 0001179110-18-011567 · edgar.xml · nonDerivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmploye Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001179110-18-011179 · edgar.xml · derivative · entry 3 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,500 Underlying: Common Stock · 16,500 shares Expires 2026-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One fourth (1/4th) of the option vests one (1) year from March 7, 2016 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 16,500 | $3.51 | $57,860.55 |
DisclosureSEC source: 0001179110-18-011179 · edgar.xml · nonDerivative · entry 2 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $3.50 to $3.53. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares sold at each such separate price. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 16,500 | $2.54 | $41,910.00 |
DisclosureSEC source: 0001179110-18-011179 · edgar.xml · nonDerivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 22:59 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 5,000 | $2.79 | $13,932.00 |
DisclosureSEC source: 0001179110-18-009506 · edgar.xml · nonDerivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26,2018. F2 · shares: The Reporting Person purchased these shares on June 29, 2018 under the Issuer's Employee Stock Purchase Plan. F3 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $2.76 to $2.80. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:33 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-18-006678 · edgar.xml · derivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: On February 2, 2017 the reporting person was granted an option to purchase 150,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On May 9, 2018, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| April 20, 2018 Filed Apr 25, 2018 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 5,000 | $4.11 | $20,550.00 |
DisclosureSEC source: 0001179110-18-005850 · edgar.xml · nonDerivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018. F2 · shares: The Reporting Person purchased these shares on December 29, 2017 under the Employee Stock Purchase Plan. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 23:30 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-18-001142 · edgar.xml · derivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2018. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 21:39 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 5,000 | $2.69 | $13,427.00 |
DisclosureSEC source: 0001179110-17-010231 · edgar.xml · nonDerivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2016. F2 · shares: The Reporting Person purchased these shares on 6/30/17 under the Employee Stock Purchase Plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.65 to $2.75, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the range set forth in footnote three (3) of this Form 4. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 00:25 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-17-001818 · edgar.xml · derivative · entry 1 Duliege Anne-Marie · CIK 0001419579 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The shares vest monthly over four (4) years from January 1, 2017. Read SEC document |
| January 03, 2017 Filed Jan 13, 2017 23:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 5,000 | $2.41 | $12,027.50 |
DisclosureSEC source: 0001179110-17-000942 · edgar.xml · nonDerivative · entry 2 Duliege Anne-Marie · CIK 0001419579 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2016 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.36 to $2.44, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.